MX2009002235A - Formulaciones de dosis oral, solidas, de liberacion controlada que comprenden nisoldipina. - Google Patents

Formulaciones de dosis oral, solidas, de liberacion controlada que comprenden nisoldipina.

Info

Publication number
MX2009002235A
MX2009002235A MX2009002235A MX2009002235A MX2009002235A MX 2009002235 A MX2009002235 A MX 2009002235A MX 2009002235 A MX2009002235 A MX 2009002235A MX 2009002235 A MX2009002235 A MX 2009002235A MX 2009002235 A MX2009002235 A MX 2009002235A
Authority
MX
Mexico
Prior art keywords
calcium channel
channel blocker
formulation
nisoldipine
core
Prior art date
Application number
MX2009002235A
Other languages
English (en)
Spanish (es)
Inventor
Guy Vergnault
Pascal Grenier
Alain Nhamias
Original Assignee
Jagotec Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38686769&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2009002235(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Jagotec Ag filed Critical Jagotec Ag
Publication of MX2009002235A publication Critical patent/MX2009002235A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2009002235A 2006-08-30 2007-08-29 Formulaciones de dosis oral, solidas, de liberacion controlada que comprenden nisoldipina. MX2009002235A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US82405406P 2006-08-30 2006-08-30
US82404306P 2006-08-30 2006-08-30
PCT/EP2007/007545 WO2008025532A1 (en) 2006-08-30 2007-08-29 Controlled release solid oral dosage formulations comprising nisoldipine

Publications (1)

Publication Number Publication Date
MX2009002235A true MX2009002235A (es) 2009-03-13

Family

ID=38686769

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2009002235A MX2009002235A (es) 2006-08-30 2007-08-29 Formulaciones de dosis oral, solidas, de liberacion controlada que comprenden nisoldipina.
MX2009002236A MX2009002236A (es) 2006-08-30 2007-08-29 Formulaciones de dosis oral de liberacion controlada que comrpenden un nucleo y una o mas capas de barrera.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2009002236A MX2009002236A (es) 2006-08-30 2007-08-29 Formulaciones de dosis oral de liberacion controlada que comrpenden un nucleo y una o mas capas de barrera.

Country Status (10)

Country Link
US (3) US20080057123A1 (enExample)
EP (2) EP2063872B2 (enExample)
JP (3) JP2010501609A (enExample)
KR (2) KR20090065519A (enExample)
AU (2) AU2007291506A1 (enExample)
CA (2) CA2662122A1 (enExample)
ES (1) ES2547226T5 (enExample)
MX (2) MX2009002235A (enExample)
WO (2) WO2008025532A1 (enExample)
ZA (1) ZA200901688B (enExample)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7431710B2 (en) 2002-04-08 2008-10-07 Glaukos Corporation Ocular implants with anchors and methods thereof
MX2009001248A (es) 2006-08-03 2009-02-11 Nitec Pharma Ag Tratamiento con glucocorticoide de liberacion prolongada de enfermedad reumatoide.
KR20090065519A (ko) 2006-08-30 2009-06-22 자고텍 아게 니솔디핀을 포함하는 방출 제어형 고형 경구 투여 제제
BRPI0721883A2 (pt) * 2007-07-23 2014-02-18 Pharmathen Sa Composição farmacêutica contendo antagonista de canal de cálcio de dihidropiridina e processo para a preparação da mesma
MX336789B (es) * 2007-08-13 2016-02-02 Inspirion Delivery Technologies Llc Farmacos resistentes al abuso, metodo de uso y metodo de fabricacion.
CN104127368A (zh) 2008-03-11 2014-11-05 武田药品工业株式会社 口腔崩解固体制剂
CN102170874A (zh) 2008-08-06 2011-08-31 高思福斯中心（控股）有限公司 治疗精神病学障碍的组合物和方法
CA2735460A1 (en) * 2008-08-29 2010-03-04 The Uab Research Foundation Novel anti-arrhythmia agent
KR20100069170A (ko) * 2008-12-16 2010-06-24 삼일제약주식회사 라시디핀 함유 과립 및 이를 포함하는 약학 조성물
EP2391369A1 (en) * 2009-01-26 2011-12-07 Nitec Pharma AG Delayed-release glucocorticoid treatment of asthma
US20100247646A1 (en) * 2009-03-26 2010-09-30 Ranbaxy Laboratories Limited Extended release tablets of nisoldipine
US20100260842A1 (en) * 2009-04-06 2010-10-14 Rashmi Nair Pseudoephedrine pharmaceutical formulations
US20100285125A1 (en) * 2009-05-07 2010-11-11 Padma Venkitachalam Devarajan Delivery system for poorly soluble drugs
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
EP4289416A3 (en) 2009-05-18 2024-01-03 Dose Medical Corporation Drug eluting ocular implant
US12478503B2 (en) 2009-05-18 2025-11-25 Glaukos Corporation Implants with controlled drug delivery features and methods of using same
EP2451274B1 (en) 2009-07-08 2017-10-04 Charleston Laboratories, Inc. Pharmaceutical compositions
MX365650B (es) 2009-12-02 2019-06-10 Adamas Pharmaceuticals Inc Composiciones de amantadina y metodos para su uso.
US20110217373A1 (en) * 2010-01-29 2011-09-08 Kumaravel Vivek Extended release pharmaceutical compositions of guanfacine hydrochloride
CN102858373B (zh) * 2010-03-31 2014-11-26 持田制药株式会社 易服用性固体制剂
EP2643001A4 (en) * 2010-11-22 2014-02-19 Glaxosmithkline Ip Dev Ltd METHOD OF TREATING CANCER
US9668915B2 (en) 2010-11-24 2017-06-06 Dose Medical Corporation Drug eluting ocular implant
AP3815A (en) 2010-12-22 2016-09-30 Purdue Pharma Lp Encased tamper resistant controlled release dosage forms
PH12013501345A1 (en) 2010-12-23 2022-10-24 Purdue Pharma Lp Tamper resistant solid oral dosage forms
US10245178B1 (en) 2011-06-07 2019-04-02 Glaukos Corporation Anterior chamber drug-eluting ocular implant
GB201111712D0 (en) 2011-07-08 2011-08-24 Gosforth Ct Holdings Pty Ltd Pharmaceutical compositions
EP2762167A4 (en) 2011-09-30 2015-12-09 Mochida Pharm Co Ltd EASY TO TAKE UP SOLID PREPARATION
JP2015537029A (ja) 2012-11-14 2015-12-24 ダブリュー・アール・グレース・アンド・カンパニー−コーンＷ Ｒ Ｇｒａｃｅ ＆ Ｃｏ−Ｃｏｎｎ 生物学的に活性な物質及び不規則性無機酸化物を含有する組成物
SG11201506064UA (en) 2013-02-05 2015-08-28 Purdue Pharma Lp Tamper resistant pharmaceutical formulations
US20140275038A1 (en) 2013-03-15 2014-09-18 Inspirion Delivery Technologies, Llc Abuse deterrent compositions and methods of use
US10751287B2 (en) 2013-03-15 2020-08-25 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
US10154971B2 (en) 2013-06-17 2018-12-18 Adamas Pharma, Llc Methods of administering amantadine
KR102170642B1 (ko) * 2013-11-14 2020-10-27 코웨이 주식회사 기능성 제재 공급기 및 이를 포함하는 연수기
US20150342875A1 (en) 2014-05-29 2015-12-03 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
US10729685B2 (en) 2014-09-15 2020-08-04 Ohemo Life Sciences Inc. Orally administrable compositions and methods of deterring abuse by intranasal administration
WO2017040853A1 (en) 2015-09-02 2017-03-09 Glaukos Corporation Drug delivery implants with bi-directional delivery capacity
WO2017053885A1 (en) 2015-09-25 2017-03-30 Glaukos Corporation Punctal implants with controlled drug delivery features and methods of using same
CA3012698A1 (en) * 2016-02-05 2017-08-10 Entrega Inc. Oral dosage form with drying agent for delivery of active agent
CA3055170A1 (en) 2016-03-04 2017-09-08 Charleston Laboratories, Inc. Pharmaceutical compositions
WO2017184881A1 (en) 2016-04-20 2017-10-26 Harold Alexander Heitzmann Bioresorbable ocular drug delivery device
US10588974B2 (en) 2016-04-22 2020-03-17 Receptor Holdings, Inc. Fast-acting plant-based medicinal compounds and nutritional supplements
EA201892396A1 (ru) 2016-12-02 2019-04-30 Ресептор Лайф Сайенсиз, Инк. Быстродействующие растительные лекарственные соединения и биологически активные добавки
US20200121652A1 (en) * 2017-06-16 2020-04-23 The Doshisha Compounds having caspase inhibitory activity, pharmaceutical agent containing said compounds and for treating or preventing corneal endothelial symptoms, disorders, or diseases, and application of said pharmaceutical agent
CN110944668A (zh) 2017-06-16 2020-03-31 学校法人同志社 用于治疗或预防眼部症状、障碍或疾病的包含mTOR抑制剂的药物及其应用
BR112020003375A2 (pt) 2017-08-24 2020-08-25 Adamas Pharma, Llc composições de amantadina, preparações das mesmas, e métodos de uso
FI3684344T3 (fi) * 2017-10-25 2025-10-08 Chiesi Farm Spa Viivästetyn vapautumisen deferipronitabletit ja niiden käyttömenetelmät
JP7566336B2 (ja) 2018-11-19 2024-10-15 スポーク・サイエンシズ・インコーポレイテッド カンナビノイド由来組成物の吸収変動を低減するｎ－アシル化脂肪アミノ酸
IT201800011120A1 (it) * 2018-12-14 2020-06-14 Dpl Pharma S P A Composizioni farmaceutiche orali solide per la somministrazione di mesalazina o suoi derivati
US20220331257A1 (en) * 2019-03-01 2022-10-20 Avadel Legacy Pharmaceuticals, Llc Liquid pharmaceutical compositions with stable drug release profiles
CN114630656B (zh) * 2019-08-26 2025-03-21 埃斯普投资有限公司 黏膜黏附剂组合物及其使用方法
WO2023089553A1 (en) * 2021-11-19 2023-05-25 Berlia Sushma Paul Controlled release formulations of flavoxate and process for preparation thereof

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62120315A (ja) * 1985-11-20 1987-06-01 Shin Etsu Chem Co Ltd 経口投与型徐放性錠剤の製造方法
DE3636123A1 (de) 1986-10-23 1988-05-05 Rentschler Arzneimittel Arzneizubereitungen zur oralen verabreichung, die als einzeldosis 10 bis 240 mg dihydropyridin enthalten
US5015479A (en) 1987-02-02 1991-05-14 Seamus Mulligan Sustained release capsule or tablet formulation comprising a pharmaceutically acceptable dihydropyridine
US4968508A (en) * 1987-02-27 1990-11-06 Eli Lilly And Company Sustained release matrix
DE3720757A1 (de) 1987-06-24 1989-01-05 Bayer Ag Dhp-manteltablette
NO883326L (no) * 1987-08-11 1989-02-13 Bayer Ag Dhp-retard-tilberedning.
DE3814532A1 (de) * 1988-04-29 1989-11-09 Bayer Ag Dhp-retard-zubereitung
IT1237904B (it) 1989-12-14 1993-06-18 Ubaldo Conte Compresse a rilascio a velocita' controllata delle sostanze attive
US5209933A (en) * 1990-01-10 1993-05-11 Syntex (U.S.A.) Inc. Long acting calcium channel blocker composition
IT1251153B (it) * 1991-08-06 1995-05-04 Vectorpharma Int Composizioni farmaceutiche solide per somministrazione orale aventi proungata residenza gastrica
IL104192A (en) * 1992-02-17 1998-01-04 Siegfried Ag Pharma Pharmaceutical dosage forms having prolonged release rate of zero order of the active ingredient
US6235313B1 (en) * 1992-04-24 2001-05-22 Brown University Research Foundation Bioadhesive microspheres and their use as drug delivery and imaging systems
US6210714B1 (en) * 1993-11-23 2001-04-03 Euro-Celtique S.A. Immediate release tablet cores of acetaminophen having sustained-release coating
IT1265240B1 (it) * 1993-11-30 1996-10-31 Ekita Investments Nv Compressa farmaceutica a rilascio controllato, di forma lenticolare
GB9402203D0 (en) 1994-02-04 1994-03-30 Smithkline Beecham Plc Pharmaceutical formulation
US6103263A (en) 1994-11-17 2000-08-15 Andrx Pharmaceuticals, Inc. Delayed pulse release hydrogel matrix tablet
JP2849047B2 (ja) * 1994-12-19 1999-01-20 大正薬品工業株式会社 ジクロフェナクナトリウム持続性製剤およびその製法
US5534263A (en) * 1995-02-24 1996-07-09 Alza Corporation Active agent dosage form comprising a matrix and at least two insoluble bands
US6083532A (en) * 1995-03-01 2000-07-04 Duramed Pharmaceuticals, Inc. Sustained release formulation containing three different types of polymers and tablet formed therefrom
US5736159A (en) 1995-04-28 1998-04-07 Andrx Pharmaceuticals, Inc. Controlled release formulation for water insoluble drugs in which a passageway is formed in situ
US5900425A (en) * 1995-05-02 1999-05-04 Bayer Aktiengesellschaft Pharmaceutical preparations having controlled release of active compound and processes for their preparation
US5783212A (en) * 1996-02-02 1998-07-21 Temple University--of the Commonwealth System of Higher Education Controlled release drug delivery system
IT1282576B1 (it) 1996-02-06 1998-03-31 Jagotec Ag Compressa farmaceutica atta a cedere la sostanza attiva in tempi successivi e predeterminabili
IT1282650B1 (it) * 1996-02-19 1998-03-31 Jagotec Ag Compressa farmaceutica,caratterizzata da elevato aumento di volume a contatto con liquidi biologici
US6096339A (en) 1997-04-04 2000-08-01 Alza Corporation Dosage form, process of making and using same
US5955096A (en) 1996-06-25 1999-09-21 Brown University Research Foundation Methods and compositions for enhancing the bioadhesive properties of polymers using organic excipients
IT1289160B1 (it) 1997-01-08 1998-09-29 Jagotec Ag Compressa farmaceutica completamente rivestita per il rilascio controllato di principi attivi che presentano problemi di
US5922352A (en) * 1997-01-31 1999-07-13 Andrx Pharmaceuticals, Inc. Once daily calcium channel blocker tablet having a delayed release core
IT1294760B1 (it) 1997-09-03 1999-04-12 Jagotec Ag Procedimento per la preparazione di compresse farmaceutiche in grado di cedere,secondo schemi predeterminabili, principi attivi poco
EP1146862B1 (de) * 1999-01-29 2003-04-23 Disphar International B.V. Pharmazeutische zusammensetzungen
DE19906290A1 (de) * 1999-02-15 2000-08-17 Falk Pharma Gmbh Arzneimittel zur Behandlung bzw. Prävention von Darmkrebs
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
AR030557A1 (es) * 2000-04-14 2003-08-27 Jagotec Ag Una tableta en multicapa de liberacion controlada y metodo de tratamiento
US6866866B1 (en) * 2000-11-03 2005-03-15 Andrx Labs, Llc Controlled release metformin compositions
DE10115216A1 (de) * 2001-03-28 2002-10-10 Bosch Gmbh Robert Kraftstoffeinspritzventil für Brennkraftmaschinen
US20040198789A1 (en) * 2003-02-28 2004-10-07 Recordati Ireland Limited Lercanidipine/ARB/diuretic therapeutic combinations
EP2359817B1 (en) 2003-03-28 2018-01-10 Sigmoid Pharma Limited Solid oral dosage form containing seamless microcapsules
JP2005132803A (ja) * 2003-10-31 2005-05-26 Ono Pharmaceut Co Ltd 胃内滞留固形剤
WO2005070462A2 (en) * 2004-01-12 2005-08-04 Sepracor, Inc. Compositions comprising (s)-amlodipine and an angiotensin receptor blocker and methods of their use
EP1811979B1 (en) * 2004-09-27 2008-11-05 Sigmoid Pharma Limited Microcapsules comprising a methylxanthine and a corticosteroid
KR20090065519A (ko) 2006-08-30 2009-06-22 자고텍 아게 니솔디핀을 포함하는 방출 제어형 고형 경구 투여 제제

Also Published As

Publication number Publication date
ES2547226T5 (es) 2020-06-12
US20080063711A1 (en) 2008-03-13
JP5788547B2 (ja) 2015-09-30
MX2009002236A (es) 2009-03-13
ES2547226T3 (es) 2015-10-02
ZA200901688B (en) 2014-02-26
EP2063872B1 (en) 2015-05-06
EP2063872A1 (en) 2009-06-03
AU2007291509B2 (en) 2013-05-02
WO2008025532A1 (en) 2008-03-06
US20160008288A1 (en) 2016-01-14
WO2008025535A1 (en) 2008-03-06
US9101544B2 (en) 2015-08-11
KR20090065520A (ko) 2009-06-22
AU2007291506A1 (en) 2008-03-06
CA2662123A1 (en) 2008-03-06
JP2010501609A (ja) 2010-01-21
JP2014114323A (ja) 2014-06-26
KR20090065519A (ko) 2009-06-22
EP2063871A1 (en) 2009-06-03
JP2010501607A (ja) 2010-01-21
CA2662122A1 (en) 2008-03-06
CA2662123C (en) 2015-12-01
US9622980B2 (en) 2017-04-18
KR101575679B1 (ko) 2015-12-08
EP2063872B2 (en) 2019-12-04
AU2007291509A1 (en) 2008-03-06
US20080057123A1 (en) 2008-03-06

Similar Documents

Publication Publication Date Title
US9101544B2 (en) Controlled release nisoldipine compositions
US20250073216A1 (en) Pharmaceutical Compositions Of Metabotropic Glutamate 5 Receptor (MGLU5) Antagonists
US8865213B2 (en) Modified release pharmaceutical compositions
PL196263B1 (pl) Farmaceutyczna postać dawkowania o przedłużonym uwalnianiu ranolazyny do stosowania ustnego
CZ365597A3 (cs) Třífázová farmaceutická forma s konstantním a řízeným uvolňováním amorfní účinné složky na jednorázové denní podávání
AU2011288556B2 (en) Pharmaceutical compositions of metabotropic glutamate 5 receptor (mGlu5) antagonists
CN101516352A (zh) 包含尼索地平的控释固体口服制剂
US20080221174A1 (en) Controlled release nisoldipine compositions
EP3796908B1 (en) Controlled release propiverine formulations
US20120064161A1 (en) Modified release niacin pharmaceutical formulations
WO2010134938A1 (en) Modified release niacin pharmaceutical formulations

Legal Events

Date Code Title Description
HH Correction or change in general